You are viewing all resources.
Intervention complexity — a conceptual framework to inform priority-setting in health
Implications of the current tuberculosis treatment landscape for future regimen change
Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience
What influences government adoption of vaccines in developing countries? A policy process analysis
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya
Using evidence to change antimalarial drug policy in Kenya
Accelerating Policy Decisions to Adopt Haemophilus influenzae Type b Vaccine: A Global, Multivariable Analysis
Vaccine innovation done differently
Widdus, 2010. Bull WHO 88:880. Context for and achievements of the product development partnership model.
The role of Product Development Partnerships in research and development for neglected diseases
Moran, M., et al. 2010. Int. Health 2:114. Based on the G-FINDER survey, the authors analyze 2007 funding of product development partnerships.
Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships
Brooks et al. 2010. Innov. Strat. Today 3:1. Based on a 2008 meeting of access representatives from product development partnerships, this paper defines “access” from the PDP perspective.
Dengue vaccine roll-out: getting ahead of the game
Bull WHO 89:476, 2011. A report on how the Dengue Vaccine Initiative is planning access strategies prior to launch.
PneumoADIP: An Example of Translational Research to Accelerate Pneumococcal Vaccination in Developing Countries
Levine, O.S., et al. 2004. An explanation of how PneumoADIP was planned to increase access to new pneumococcal vaccines.